A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Files

Published: 16 March 2021| Version 1 | DOI: 10.17632/f5jkpm4mxh.1
Contributor:
Brett King

Description

Supplementary Figures 1-6. Supplementary Tables 1-5

Files